Emily Schonfeld

Acute kidney injury (AKI) and chronic kidney disease (CKD) are common conditions among patients with cirrhosis whose development is associated with increased morbidity and mortality. Recurrent episodes of AKI within this population can ultimately lead to CKD, while patients with underlying CKD are in turn more likely to experience AKI. Determining the etiology of kidney dysfunction in the setting of cirrhosis is often challenging given the considerable limitations of currently available diagnostic tools. Ongoing research into the role of novel serum and urine biomarkers may allow for more timely diagnosis and treatment of kidney injury among patients with cirrhosis. This review provides an overview of kidney dysfunction in cirrhosis with a focus on the role of these emerging biomarkers for diagnosis of AKI and CKD.

Purpose Polycystic liver disease is the most prevalent extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Non-obstructive asymptomatic common bile duct (CBD) dilatation has been observed anecdotally on CT scans, but CT is not optimal for biliary visualization. Here, we measured CBD diameter on T2-weighted MRI in ADPKD subjects to determine if CBD dilatation is associated with ADPKD. Methods CBD diameter was measured retrospectively on ADPKD subjects (n = 254) and on age- and sex-matched controls without ADPKD (n = 254) who underwent abdominal MRI. CBD diameter in these groups was compared and correlated with clinical, laboratory and magnetic resonance imaging (MRI) features, including organ volumes and cyst burden. Results CBD median diameter [interquartile range, IQR, 25%, 75%] was 22% larger in ADPKD compared to controls (5.6 [4.7, 6.9] mm vs. 4.6 [3.9, 5.4] mm, p < 0.001). CBD diameter measurements had excellent inter-observer agreement (Intraclass correlation coefficient = 0.92). Thirteen (5.1%) ADPKD subjects had a CBD diameter ≥ 10 mm compared to 1 (0.4%) control subject (p < 0.001). Multivariable analysis found the presence of PKD1 or PKD2 mutation (beta = 1.5, P < 0.001) and age (beta = 0.04, p < 0.001) to be associated with increased CBD diameter and serum albumin associated with decreased CBD diameter (beta=-0.39, p < 0.001). Conclusion ADPKD subjects had 22% larger CBD diameters than in non-ADPKD controls and were more likely to have CBD dilatation ≥ 10 mm without CBD obstruction. Awareness of this association of non-obstructive CBD dilatation with ADPKD may limit unnecessary diagnostic testing.

Export {"href":"Single Video Player","role":"media-player-id","content-type":"play-in-place","position":"float","orientation":"portrait","label":"","caption":"","object-id":[{"pub-id-type":"doi","id":""},{"pub-id-type":"other","content-type":"media-stream-id","id":"1_9udfl750"},{"pub-id-type":"other","content-type":"media-source","id":"Kaltura"}]}

Background: Hospital admissions for patients with cirrhosis continue to increase. In New York City, 25% to 30% of hospitalized cirrhotics are readmitted within 30 days. Rehospitalization is associated with increased mortality, poor quality of life, and financial burden to patients, hospitals, and payers. Preventable readmissions are partially accounted for by a well-documented quality gap between evidence-based guidelines for cirrhosis management and real-world adherence to these recommendations. Methods: We performed a prospective cohort study that compared outcomes among cirrhotic patients admitted to 4 internal medicine teams over a 6-month period. An electronic medical record (EMR) note template that outlined best-practice measures for cirrhotics was developed. Inpatient providers on 2 teams were instructed to include it in daily progress notes and discharge summaries. The recommended practices included diagnostic paracentesis and diuretics for ascites, rifaximin, and lactulose for hepatic encephalopathy, beta blockers for esophageal varices, and antibiotic prophylaxis for spontaneous bacterial peritonitis. The remaining 2 teams continued the standard of care for cirrhotic patients. The primary outcome was 30-day readmissions. Secondary outcomes included in-hospital mortality, 30-day mortality, length of stay, and adherence to best-practice guidelines. Results: Over a 6-month period, 108 cirrhotic patients were admitted, 83 in the interventional group and 25 in the control group. MELD-Na scores on admission did not differ between the groups (20.1 vs. 21.1, P=0.56). Thirty-day readmissions were not significantly different between the interventional and control groups (19.3% vs. 24%, P=0.61). However, 30-day mortality was significantly lower in the interventional group (8.4% vs. 28%, P=0.01). There was no difference between the 2 groups in in-hospital mortality (4.8% vs. 0%, P=0.27), 90-day mortality (15.7% vs. 28.0%, P=0.17) or length of stay (10.2 vs. 12.6 d, P=0.34). Adherence to best-practice metrics was similar between the groups, except for rates of diagnostic paracentesis, which were higher in the interventional group (98% vs. 80%, P=0.01). Conclusion: Implementation of an EMR note template with cirrhosis best practices was associated with lower 30-day mortality and higher rates of diagnostic paracentesis among admitted patients with cirrhosis. These findings suggest that the integration of best-practice measures into the EMR may improve outcomes in hospitalized cirrhotic patients. Larger studies are required to validate these findings.